European data on stem cell mobilization with plerixafor in patients with nonhematologic diseases: an analysis of the European consortium of stem cell mobilization
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F12%3A%230001725" target="_blank" >RIV/65269705:_____/12:#0001725 - isvavai.cz</a>
Výsledek na webu
<a href="http://dx.doi.org/10.1111/j.1537-2995.2012.03603.x" target="_blank" >http://dx.doi.org/10.1111/j.1537-2995.2012.03603.x</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/j.1537-2995.2012.03603.x" target="_blank" >10.1111/j.1537-2995.2012.03603.x</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
European data on stem cell mobilization with plerixafor in patients with nonhematologic diseases: an analysis of the European consortium of stem cell mobilization
Popis výsledku v původním jazyce
BACKGROUND: Plerixafor with granulocyte-colony-stimulating factor (G-CSF) has been shown to enhance stem cell mobilization in patients with multiple myeloma and lymphoma with previous mobilization failure. In this European named patient program we reportthe experience in insufficiently mobilizing patients diagnosed with nonhematologic diseases. STUDY DESIGN AND METHODS: Thirty-three patients with germ cell tumor (n=11), Ewing sarcoma (n=6), Wiscott-Aldrich disease (n=5), neuroblastoma (n=4), and othernonhematologic diseases (n=7) were included in the study. Plerixafor was limited to patients with previous or current stem cell mobilization failure and given after 4 days of G-CSF (n=21) or after chemotherapy and G-CSF (n=12) in patients who mobilized poorly. RESULTS: Overall, 28 (85%) patients succeeded in collecting at least 2x10(6)/kg body weight (b.w.) CD34+ cells (median, 5.0x10(6)/kg b.w. CD34+ cells; range, 2.0x10(6)-29.5x10(6)/kg b.w. CD34+ cells), and five (15%) patients collec
Název v anglickém jazyce
European data on stem cell mobilization with plerixafor in patients with nonhematologic diseases: an analysis of the European consortium of stem cell mobilization
Popis výsledku anglicky
BACKGROUND: Plerixafor with granulocyte-colony-stimulating factor (G-CSF) has been shown to enhance stem cell mobilization in patients with multiple myeloma and lymphoma with previous mobilization failure. In this European named patient program we reportthe experience in insufficiently mobilizing patients diagnosed with nonhematologic diseases. STUDY DESIGN AND METHODS: Thirty-three patients with germ cell tumor (n=11), Ewing sarcoma (n=6), Wiscott-Aldrich disease (n=5), neuroblastoma (n=4), and othernonhematologic diseases (n=7) were included in the study. Plerixafor was limited to patients with previous or current stem cell mobilization failure and given after 4 days of G-CSF (n=21) or after chemotherapy and G-CSF (n=12) in patients who mobilized poorly. RESULTS: Overall, 28 (85%) patients succeeded in collecting at least 2x10(6)/kg body weight (b.w.) CD34+ cells (median, 5.0x10(6)/kg b.w. CD34+ cells; range, 2.0x10(6)-29.5x10(6)/kg b.w. CD34+ cells), and five (15%) patients collec
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FD - Onkologie a hematologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Ostatní
Rok uplatnění
2012
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Transfusion
ISSN
0041-1132
e-ISSN
—
Svazek periodika
52
Číslo periodika v rámci svazku
11
Stát vydavatele periodika
US - Spojené státy americké
Počet stran výsledku
6
Strana od-do
2395-2400
Kód UT WoS článku
000310977500017
EID výsledku v databázi Scopus
—